Metformin: intrinsic vasculoprotective properties.
Wiernsperger
N F
NF
LiPHA/INSERM U, 352 Diabetic Microangiopathy Research Unit, F-69621 Villeurbanne, France. nicolas.wiernsperger@lipha.fr
D000818:Animals; D002317:Cardiovascular Agents; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D006031:Glycosylation; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010084:Oxidation-Reduction
D002317:Cardiovascular Agents; D007004:Hypoglycemic Agents; D008687:Metformin